Roger J. Diegel

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Hypoxia augments cytokine (transforming growth factor-beta (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts

Brygida Berse, Jane A. Hunt, Roger J. Diegel et al. · Clinical & Experimental Immunology · 1999 · 199 citations · Full text

Analysis of the function, expression, and subcellular distribution of human tristetraprolin

Seth A. Brooks, John E. Connolly, Roger J. Diegel et al. · Arthritis & Rheumatism · 2002 · 61 citations · Full text

Case series: rheumatological manifestations attributed to exposure to Libby Asbestiform Amphiboles

Roger J. Diegel, Brad Black, Jean C. Pfau et al. · Journal of Toxicology and Environmental Health · 2018 · 16 citations